Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This consensus from 22 Spanish dermatologists recommends using a multimodal therapy starting with oral dutasteride, combined with topical and/or intralesional agents, and adding hydroxychloroquine if inflammation persists, to manage frontal fibrosing alopecia due to its irreversible hair loss and lack of specific approved treatments.

This study found that decorin treatment significantly enhances dermal papilla cell proliferation, promoting hair follicle growth by influencing the SMAD3/TGF-β signaling pathway through exosomal miR-129–2-3p, which may aid in novel strategies for treating hair disorders and enhancing wool production.

This article reviews the characteristics and presentation of fibrosing alopecia in a pattern distribution, a form of scarring alopecia similar to androgenetic alopecia and lichen planopilaris, but provides no new clinical findings.

This study suggests that using UVFD to examine non-pigmented facial lesions can potentially enhance diagnostic accuracy and reduce unnecessary biopsies.

This study found that Fos protein expression is closely linked to epithelial cell differentiation, particularly during cornification and cell death, with overexpression observed in keratinization-blocked mutant epidermis.

This study demonstrated that caffeine, minoxidil, and the HIF-1α-stimulating agent deferiprone significantly enhanced dermal papilla cell proliferation in a 3D culture model, suggesting deferiprone as a potential alternative to minoxidil.

Among patients with biopsy-proven FAPD in specialized hair clinics, this study found the condition is common in females around 52.5 years old, with treatment generally stabilizing or slightly improving hair loss, despite challenges in differentiating FAPD from androgenetic alopecia.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

This study observed that using a 1064 nm Nd: YAG laser may stabilize hair loss and promote new growth in some females with frontal fibrosing alopecia, though individual results varied.

This study used Density Functional Theory to calculate finasteride's molecular properties, finding the GGA/PW91 method aligns well with experimental data and identifying key reactive sites for chemical interactions.

In this retrospective study, oral minoxidil was found to improve the density of the frontotemporal hairline in 45.1% of patients with frontal fibrosing alopecia, with some also experiencing eyebrow and eyelash growth; however, adverse effects such as hypertrichosis were noted in 33.6% of the participants.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This study demonstrated that FGF5s acts as an inhibitor of FGF5 in regulating hair growth cycles in cashmere goat dermal papilla cells.

This study found that a 22-bp InDel polymorphism in the FGF7 gene was significantly associated with growth traits in goats, with genotypes ID and/or II linked to better growth compared to genotype DD, indicating its potential as a molecular marker in breeding programs.

In this study, a topical formulation with compounds from the monoterpenoid family significantly improved hair growth indicators like anagen:telogen ratio, hair fall, and visual hair density in men and women with pattern hair loss.

This report from the UK reviews the literature on post-menopausal frontal fibrosing alopecia and highlights its under-recognition and distinctive characteristics compared to lichen planopilaris, but does not provide new results.

Red dots on the upper chest may be an early sign of certain types of hair loss.

This article reports a case of frontal fibrosing alopecia in its early inflammatory stage that responded positively to intralesional steroid treatment.

This study found that fermented Morinda citrifolia extract enhances the viability and cycle progression of human dermal papilla cells and promotes hair growth through Wnt/β-catenin signaling activation, suggesting its potential as a therapeutic candidate for alopecia.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This review provides a detailed analysis of frontal fibrosing alopecia, focusing on its prevalence in postmenopausal Caucasian women, associated comorbidities, and potential autoimmune, genetic, hormonal, and environmental factors; it emphasizes the need for improved understanding to enhance diagnosis and treatment.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.

This study demonstrated that a metric based on rotational echo intensity in 2H magic-angle spinning NMR can derive kinetic information for conformational exchange without complex modelling, achieving activation barriers consistent with prior findings.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This research found that liposome drug delivery systems, particularly with targeted modifications, show promise for improving effectiveness and reducing toxicity in combination cancer therapies.

This study found that adding fexofenadine to DPCP treatment in non-atopic Alopecia areata patients did not significantly improve hair regrowth, but it did significantly reduce treatment-related discomfort.

In this open uncontrolled study on microneedling as an adjuvant therapy for frontal fibrosing alopecia, researchers observed stable frontotemporal recession measurements while patients reported improvements in quality of life and a reduction in inflammatory activity parameters.

This editorial response discusses the evidence for using 5-alpha reductase inhibitors in treating frontal fibrosing alopecia, acknowledging its potential benefits while emphasizing the need for further studies to establish it as a standard treatment.